News

Celldex Ends Barzolvolimab Development In Atopic Dermatitis After Phase 2 Trial Misses Key Endpoints

NASDAQ

(RTTNews) - Celldex Therapeutics, Inc. (CLDX) on Thursday stated it is discontinuing development of barzolvolimab in atopic dermatitis (AD) after the Phase 2 trial missed its primary and secondary endpoints.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.